HNF4A and GATA6 loss reveals therapeutically actionable subtypes in pancreatic cancer

Holly Brunton, Giuseppina Caligiuri, Richard Cunningham, Rosie Upstill-Goddard, Ulla-Maja Bailey, Ian M. Garner, Craig Nourse, Stephan Dreyer, Marc Jones, Kim Moran-Jones, Derek W. Wright, Viola Paulus-Hock, Colin Nixon, Gemma Thomson, Nigel B. Jamieson, Grant A. McGregor, Lisa Evers, Colin J. McKay, Aditi Gulati, Rachel BroughIlirjana Bajrami, Stephen J. Pettitt, Michele L. Dziubinski, Simon T. Barry, Robert Grützmann, Robert Brown, Edward Curry, Sarah Allison, Andrew V. Biankin, David K. Chang, Susanna L. Cook, Paul Grimwood, Shane Kelly, John F. Marshall, Brian McDade, Daniel McElroy, Donna Ramsay, Selma Rebus, Jane Hair, Paul Westwood, Nicola Williams, Fraser R. Duthie, Amber L. Johns, Amanda Mawson, Christopher J. Scarlett, Mary Anne L. Brancato, Sarah J. Rowe, Skye H. Simpson, Mona Martyn-Smith, Michelle T. Thomas, Lorraine A. Chantrill, Venessa T. Chin, Angela S. Chou, Mark J. Cowley, Jeremy L. Humphris, Ronald S. Mead, Adnan M. Nagrial, Marina Pajic, Jessica Pettit, Mark Pinese, Ilse Rooman, Jianmin Wu, Jiang Tao, Renee DiPietro, Clare Watson, Angela M. Steinmann, Hongching Lee, Rachel Wong, Andreia V. Pinho, Marc Giry-Laterrière, Roger J. Daly, Elizabeth A. Musgrove, Robert L. Sutherland, Sean M. Grimmond, Nicola Waddell, Karin S. Kassahn, David K. Miller, Peter J. Wilson, Ann Marie Patch, Sarah Song, Ivon Harliwong, Senel Idrisoglu, Ehsan Nourbakhsh, Suzanne Manning, Shivangi Wani, Milena M. Gongora, Matthew L. Anderson, Oliver Holmes, Conrad R. Leonard, Darrin F. Taylor, Scott Wood, Christina W. Xu, Kátia Nones, J. Lynn Fink, Angelika N. Christ, Timothy J. Bruxner, Nicole Cloonan, Felicity S. Newell, John V. Pearson, Michael C. Quinn, Shivashankar H. Nagaraj, Stephen H. Kazakoff, Nick M. Waddell, Keerthana Krisnan, Kelly Quek, David L. Wood, Jaswinder S. Samra, Anthony J. Gill, Nick Pavlakis, Alexander D. Guminski, Christopher W. Toon, Ray Asghari, Neil D. Merrett, et al

Research output: Contribution to journalArticlepeer-review

Abstract

Pancreatic ductal adenocarcinoma (PDAC) can be divided into transcriptomic subtypes with two broad lineages referred to as classical (pancreatic) and squamous. We find that these two subtypes are driven by distinct metabolic phenotypes. Loss of genes that drive endodermal lineage specification, HNF4A and GATA6, switch metabolic profiles from classical (pancreatic) to predominantly squamous, with glycogen synthase kinase 3 beta (GSK3b) a key regulator of glycolysis. Pharmacological inhibition of GSK3b results in selective sensitivity in the squamous subtype; however, a subset of these squamous patient-derived cell lines (PDCLs) acquires rapid drug tolerance. Using chromatin accessibility maps, we demonstrate that the squamous subtype can be further classified using chromatin accessibility to predict responsiveness and tolerance to GSK3b inhibitors. Our findings demonstrate that distinct patterns of chromatin accessibility can be used to identify patient subgroups that are indistinguishable by gene expression profiles, highlighting the utility of chromatin-based biomarkers for patient selection in the treatment of PDAC.
Original languageEnglish
Article number107625
Number of pages17
JournalCell Reports
Volume31
Issue number6
DOIs
Publication statusPublished - 2020

Open Access - Access Right Statement

©2020 The Author(s). This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Keywords

  • cancer
  • pancreas
  • pancreatic acinar cells
  • pancreatic duct

Fingerprint

Dive into the research topics of 'HNF4A and GATA6 loss reveals therapeutically actionable subtypes in pancreatic cancer'. Together they form a unique fingerprint.

Cite this